News

News

Individual Testing Effective, But Timely and Costly, in Screening for Zika Virus in Blood...

In March 2016, approximately one year after Zika virus (ZIKV) infections were reported in the United States, the U.S. Food and Drug Administration (FDA)...

ASH Choosing Wisely Item Makes the ABIM Top 12, Celebrating World Sickle Cell Day,...

ASH Choosing Wisely Recommendation Makes the ABIM Top 12 The Choosing Wisely® campaign, an initiative of the American Board of Internal Medicine (ABIM) Foundation, encourages clinicians...

ACS Grants $47 Million in Funding, Stand Up to Cancer Announces Innovation Awards, and...

Lawrence B. Gardner, MD, an assistant professor of medicine and pharmacology at New York University (NYU) Langone Health, died on March 27 at age...

NDA Submitted for Duvelisib for CLL and Follicular Lymphoma

A New Drug Application (NDA) was submitted for the oral phosphoinositide 3-kinase (PI3K) dual inhibitor duvelisib for the treatment of relapsed/refractory chronic lymphocytic leukemia...

Specialty Hospitals Benefit More From CMS Star Ratings

An analysis from Modern Healthcare found that the Centers for Medicare & Medicaid Services’ (CMS) star-ratings formula disproportionately benefits specialty hospitals, compared with major teaching...

FDA Expands Approval of Blinatumomab for MRD-Positive ALL

The U.S. Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee voted 8-4 in favor of accelerated approval for the bispecific antibody blinatumomab for...

Researchers Call for Revised Clinical Trial Criteria

Nearly 20 percent of publicly funded U.S. cancer clinical trials cannot enroll enough participants for the study to continue, and researchers are looking to...
WIB_icon

Study Finds Thromboembolism Is a Frequent Complication of ALL Treatment

Adolescents and adults with acute lymphocytic leukemia (ALL) are at a “markedly” increased risk for developing thromboembolism (TE), even when treated according to the...

Evaluating Daratumumab as Frontline Treatment of Transplant-Ineligible Myeloma

Results from a prespecified interim analysis from the phase III ALCYONE study found that the addition of daratumumab to standard care (bortezomib, melphalan, prednisone...

Study Finds Pharmaceutical Funding Influences Selection of Cancer Treatment

U.S. physicians and hospitals receive approximately $7 billion annually from the pharmaceutical industry. According to a research letter published in JAMA Internal Medicine, this...
Advertisement

Current Issue

June 2018, Volume 4, Issue 7

This issue features a look at gaining oral parity for cancer medications, the unavoidable "bubbles" in which people live and work, and more.